Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
A Phase 1 Study in Patients With Solid Tumors
- First Posted Date
- 2010-10-07
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 39
- Registration Number
- NCT01215916
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Brunswick, New Jersey, United States
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy
- Conditions
- Interventions
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 6
- Registration Number
- NCT01209520
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients
- Conditions
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2010-09-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 68
- Registration Number
- NCT01192243
- Locations
- 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
- Conditions
- Interventions
- First Posted Date
- 2010-08-31
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 169
- Registration Number
- NCT01192165
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-08-20
- Last Posted Date
- 2016-01-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 90
- Registration Number
- NCT01185847
Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients
- Conditions
- First Posted Date
- 2010-07-29
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 34
- Registration Number
- NCT01172470
- Locations
- 🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States
Ixabepilone and Pemetrexed/Solid Tumors
- First Posted Date
- 2010-07-27
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- University of Southern California
- Registration Number
- NCT01170871
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Los Angeles County+University of Southern California Medical Center, Los Angeles, California, United States
BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours
- First Posted Date
- 2010-07-26
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 53
- Registration Number
- NCT01169675
- Locations
- 🇨🇦
1200.92.1001 Boehringer Ingelheim Investigational Site, Edmonton, Alberta, Canada
🇨🇦1200.92.1002 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada
A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-07-19
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 19
- Registration Number
- NCT01165021
- Locations
- 🇮🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sondalo, Italy
A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 280
- Registration Number
- NCT01160744
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nottingham, Nottinghamshire, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.